Protagenic Therapeutics Stock Performance
| PTIX Stock | USD 3.48 0.09 2.52% |
Protagenic Therapeutics holds a performance score of 5 on a scale of zero to a hundred. The company holds a Beta of 1.84, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Protagenic Therapeutics will likely underperform. Use Protagenic Therapeutics potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to analyze future returns on Protagenic Therapeutics.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Protagenic Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating forward indicators, Protagenic Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.3 M | |
| Free Cash Flow | -4.2 M |
Protagenic | Build AI portfolio with Protagenic Stock |
Protagenic Therapeutics Relative Risk vs. Return Landscape
If you would invest 360.00 in Protagenic Therapeutics on April 16, 2025 and sell it today you would lose (12.00) from holding Protagenic Therapeutics or give up 3.33% of portfolio value over 90 days. Protagenic Therapeutics is currently generating 2.5607% in daily expected returns and assumes 35.2589% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Protagenic, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protagenic Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protagenic Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protagenic Therapeutics, and traders can use it to determine the average amount a Protagenic Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0726
| Best Portfolio | Best Equity | |||
| Good Returns | PTIX | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 35.26 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.56 actual daily | 51 51% of assets have lower returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Protagenic Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protagenic Therapeutics by adding it to a well-diversified portfolio.
Protagenic Therapeutics Fundamentals Growth
Protagenic Stock prices reflect investors' perceptions of the future prospects and financial health of Protagenic Therapeutics, and Protagenic Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protagenic Stock performance.
| Return On Equity | -5.13 | ||||
| Return On Asset | -1.9 | ||||
| Current Valuation | (1.75 M) | ||||
| Shares Outstanding | 868.41 K | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 1.61 X | ||||
| EBITDA | (5.47 M) | ||||
| Cash And Equivalents | 8.87 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 942.76 K | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (4.22 M) | ||||
| Earnings Per Share | (13.13) X | ||||
| Total Asset | 1.96 M | ||||
| Retained Earnings | (36.3 M) | ||||
| Current Asset | 3.75 M | ||||
| Current Liabilities | 736 K | ||||
About Protagenic Therapeutics Performance
Evaluating Protagenic Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Protagenic Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protagenic Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.Things to note about Protagenic Therapeutics performance evaluation
Checking the ongoing alerts about Protagenic Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protagenic Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protagenic Therapeutics is way too risky over 90 days horizon | |
| Protagenic Therapeutics appears to be risky and price may revert if volatility continues | |
| Protagenic Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics currently holds about 8.87 M in cash with (4.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. |
- Analyzing Protagenic Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protagenic Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protagenic Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protagenic Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protagenic Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protagenic Therapeutics' stock. These opinions can provide insight into Protagenic Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.